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Stratiﬁcation Index to Predict Heart Failure in
Patients With Stable Coronary Artery Disease
The Heart and Soul Study
Steven M. Stevens, MD,* Ramin Farzaneh-Far, MD,* Beeya Na, MPH,†
Mary A. Whooley, MD,*† Nelson B. Schiller, MD, FACC*
San Francisco, California
O B J E C T I V E S We sought to determine which transthoracic echocardiographic (TTE) measurements
most strongly predict heart failure (HF) and to develop an index for risk stratiﬁcation in outpatients with
coronary artery disease (CAD).
B A C KG ROUND Many TTE measurements have been shown to be predictive of HF, and they might
be useful if aggregated into a risk-prediction index.
METHOD S We performed TTE in 1,024 outpatients with stable CAD enrolled in the Heart and Soul study
and followed them for 4.4 years. With Cox proportional hazard models, we evaluated the association of 15
TTE measurements with subsequent HF hospital stay. Those measurements that independently predicted HF
were combined into an index. Variables were deﬁned as normal or abnormal on the basis of dichotomous
cutoffs determined from the American Society of Echocardiography. Abnormal variables in each measure-
ment were assigned points on the basis of strength of association with HF.
R E S U L T S Of the 15 variables, 5 measurements were independent predictors of HF: left ventricular mass
index (LVMI), left atrial volume index (LAVI), mitral regurgitation (MR), left ventricular outﬂow tract
velocity-time integral (VTILVOT), and diastolic dysfunction (DD). In multivariate analysis, each of the 5
measurements independently predicted HF: LVMI 90 g/m2 (hazard ratio [HR]: 4.1; 95% conﬁdence interval
[CI]: 2.3 to 7.2, p  0.0001); pseudo-normal or restrictive DD (HR: 2.9; 95% CI: 1.8 to 4.5, p  0.0001); VTILVOT
22 mm (HR: 2.2; 95% CI: 1.4 to 3.5, p  0.0004); mild, moderate, or severe MR (HR: 1.8; 95% CI: 1.2 to 2.8,
p 0.009); and LAVI29 ml/m2 (HR: 1.6; 95% CI: 1.0 to 2.5, p 0.06). Combining these measurements, the
Heart Failure Index ranged from 0 to 8, representing risk as follows: 3 points for LVMI, 2 points for DD, and
1 point for VTILVOT, MR, and LAVI. Among participants with 0 to 2 points: 4% had HF hospital stays (reference);
3 to 4 points: 10% (HR: 2.4; 95% CI: 1.3 to 4.4, p  0.003); 5 to 6 points: 24% (HR: 6.2; 95% CI: 3.6 to 10.6,
p  0.0001); 7 to 8 points: 48% (HR: 13.7; 95% CI: 7.2 to 25.9, p  0.0001).
CONC L U S I O N S We identiﬁed 5 TTE measurements that independently predict HF in patients with
stable CAD and combined them as an index that might be useful for risk stratiﬁcation and serial
observations. (J Am Coll Cardiol Img 2009;2:11–20) © 2009 by the American College of Cardiology
Foundation
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12ransthoracic 2-dimensional echocardiogram
and Doppler flow examination (TTE) gener-
ate a plethora of high-quality anatomic and
physiologic data. However, the abundance
nd variety of these data can complicate acquisition
nd analysis, limiting effective integration into clin-
cal settings. To relevantly and efficiently aggregate
his information, it is desirable to identify the most
otent predictors of dysfunction and adverse outcomes
mong them.
See page 21
Left ventricular (LV) ejection fraction
(EF) is commonly used to predict heart
failure (HF) in patients with coronary artery
disease (CAD) (1) but is an overtaxed de-
scriptor of systolic function. Numerous
TTE-derived measurements can detect sub-
tle changes in myocardial structure and
function that offer prognostic information
beyond EF. For example, left ventricular
mass index (LVMI) predicts mortality inde-
pendent of other cardiovascular risk factors
and electrocardiogram-derived LV hyper-
trophy (2). Likewise, left atrial enlargement,
mitral regurgitation (MR), and diastolic
dysfunction (DD) have been shown to pre-
dict cardiovascular events, HF, and mortal-
ity (3– 6). Other techniques such as
Doppler-derived stroke distance (i.e., left
ventricular outflow tract velocity–time inte-
gral [VTILVOT]) have potential applications
in describing global function that might
carry unique prognostic relevance (7).
The Heart and Soul Study has com-
pleted 4.4 years of follow-up on a popu-
lation of 1,024 subjects with CAD. A
comprehensive quantitative echocardio-
gram and Doppler examination was ad-
ministered to each participant at enroll-
ment. This study, therefore, provided a
uitable vehicle from which to stratify and aggregate
TE data and to determine the most effective
ombination of noninvasive parameters for the pre-
iction of congestive HF hospital stay.
We hypothesized that an array of TTE-derived
easurements shown to independently predict con-
estive HF hospital stay can be combined into a
isk-stratification index predictive of HF (the TTE
eart Failure Index). We intend for this index to be
eadily accessible and to streamline communication
se
rly
ex
r
ow
rt ofmong providers.E T H O D S
he Heart and Soul Study is a prospective cohort
tudy investigating the influence of psychosocial
actors on cardiovascular events. The enrollment
rocess for the Heart and Soul Study has been
reviously described (8). Patients were enrolled
rom 2 Departments of Veterans Affairs (San Fran-
isco and Palo Alto, California), the University of
alifornia-San Francisco, and 9 public health clin-
cs from the Community Health Network of San
rancisco. Criteria for enrollment were: 1) history
f myocardial infarction; 2) angiographic evidence
f at least 50% stenosis by area in at least 1 coronary
essel; 3) evidence of exercise-induced ischemia by
readmill electrocardiogram or stress nuclear perfu-
ion imaging; 4) history of coronary revasculariza-
ion; or 5) a prior diagnosis of coronary disease by
n internist or cardiologist. Individuals were ex-
luded if they had a myocardial infarction within
he prior 6 months, deemed themselves unable to
alk 1 block, or were planning to move out of the
ocal area within 3 years. A total of 1,024 study
articipants provided informed consent and com-
leted baseline echocardiographic and laboratory
esting, including 549 (54%) with a history of
yocardial infarction, 237 (23%) with a history of
evascularization but not myocardial infarction, and
38 (23%) with diagnosis of coronary disease that
as documented by their physician (on the basis of
positive angiogram or treadmill test in 98% of
ases). The institutional review board at each of the
nrolling centers approved the study protocol.
chocardiographic measurements. A complete rest-
ng 2-dimensional echocardiogram with an Acuson
equoia ultrasound system (Siemens Medical Solu-
ions, Mountain View, California) with a 3.5-MHz
ransducer and Doppler ultrasound examination was
erformed in all patients. Standard 2-dimensional
arasternal short-axis and apical 2- and 4-chamber
iews during quiet respiration or held expiration were
btained. Two highly experienced sonographers made
ll sonographic measurements, and a single cardiolo-
ist reader (N.B.S.), who was blinded to clinical and
aboratory information, evaluated, confirmed, and—
hen needed—corrected each measurement.
Fifteen candidate echocardiographic variables
ere chosen a priori from the data base by the
nvestigators:
1. LV end-systolic volume index
2. LV end-diastolic volume index
3. LVEFB B R E V I A T I O N S
N D A C R O N YM S
AD coronary artery disea
I confidence interval
D diastolic dysfunction
/A ratio of peak mitral ea
iastolic to atrial contraction
elocity
F ejection fraction
F heart failure
R hazard ratio
AVI left atrial volume ind
V left ventricle/ventricula
VMI left ventricular mass
ndex
VOT left ventricular outfl
ract
Rmitral regurgitation
T-proBNP N-terminal pa
he pro-B-type natriuretic
eptide
TE transthoracic
chocardiography
TI
LVOT
 left ventricular
utflow tract velocity–time
ntegral
TIRVOT right ventricular
utflow tract velocity–time4. left atrial volume index (LAVI)
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135. right atrial volume index
6. LVMI
7. pulmonary artery peak systolic pressure
8. right ventricular outflow tract velocity-time
integral (VTIRVOT)
9. VTILVOT
0. aortic valve area
1. right atrial pressure
2. DD
3. MR severity
4. tricuspid regurgitation severity
5. resting wall motion score index
Standard apical 2- and 4-chamber views were
btained. LV end-systolic and end-diastolic vol-
mes were obtained by planimetry with the biplane
ethod of discs as described (9). The LVEF was
alculated as (end-diastolic volume  end-systolic
olume)/end-diastolic volume.
Left and right atrial volumes were obtained at
nd-ventricular systole by manual planimetry with
he biplane method of discs for the left atrium and
ingle plane method of discs for the right atrium, as
reviously described and validated (10). All cham-
er volumes were subsequently indexed to body
urface area.
LV mass was calculated with a truncated ellipsoid
quation and indexed to body surface area as pre-
iously described and validated (9,11).
The tricuspid regurgitation jet was visualized
ith color flow mapping, and continuous wave
oppler was used to capture the flow signal from
easurement of peak tricuspid regurgitant velocity.
he peak tricuspid regurgitant velocity for the
urrent study was the highest measurement obtain-
ble by Doppler imaging among the parasternal,
pical, and subcostal views. The right ventricular
ystolic pressure was estimated with the modified
ernoulli equation (p  4v2) and added to the
stimated right atrial pressure to obtain the pulmo-
ary artery systolic pressure (12).
The VTIRVOT was obtained by placing a pulsed
ave Doppler sample volume in the proximal right
entricular outflow tract at the level of the pulmonic
alve, in the parasternal short-axis view and tracing
he outer boundaries of the spectral Doppler signal
o obtain the VTI. The sample volume was placed
uch that the opening valve Doppler signal was
reater than or equal to the closing signal.
The VTILVOT was obtained by placing a pulsed
ave Doppler sample volume in the left ventricular
utflow tract (LVOT) immediately proximal to the
ortic valve in the anteriorly angulated apical
-chamber view and tracing the outer boundaries of che peak spectral Doppler signal to obtain the
TILVOT. Proper location in the LVOT was con-
rmed by visualization of the aortic valve closure
ignal (7). The LVOT diameter was measured at
he level of the aortic annulus from the parasternal
ong-axis view in midsystole. The aortic valve area
as derived from the velocity-time integrals of the
ortic valve and the LVOT tract with the continuity
quation (13).
Diastolic dysfunction was defined as the presence
f at least 1 of the following: impaired relaxation
efined as a ratio of peak mitral early diastolic to
trial contraction velocity (E/A) of 0.75 with
ystolic dominant pulmonary vein flow; pseudonor-
al defined as 0.75  E/A 1.5 with diastolic
ominant pulmonary vein flow; restrictive filling
efined as an E/A 1.5 with diastolic dominant
ulmonary vein flow (14). Diastolic dysfunction
as only determined if both pulmonary vein flow
nd E/A were both recorded. Pulmonary vein flow
as recorded in 1,011 patients, and E/A was
ecorded in 971 patients.
The severity of mitral and tricuspid regurgita-
ion was determined according to American So-
iety of Echocardiography guidelines (15). The
ight atrial pressure was obtained by inspection of
he inferior vena cava during respiration as pre-
iously described (16).
Regional LV function was assessed with a stan-
ard 16-segment model (10). Segmental scores
ere assigned as follows: normal or hyperkinesis 
; hypokinesis  2; akinesis  3; dyskinesis  4;
nd aneurismal  5. The wall motion score index
as derived as the sum of all scores divided by the
umber of segments visualized.
ardiovascular outcomes. We conducted annual
elephone follow-up interviews and questioned par-
icipants or their proxies regarding recent emer-
ency room visits and hospital stays. Medical
ecords, death certificates, and coroner’s reports
ere retrieved. Participants were censored at point
f HF admission, when lost to follow-up, or upon
eath. Two blinded adjudicators reviewed each
vent, and if there was agreement, the outcome
lassification was binding. If there was disagree-
ent, a third blinded adjudicator reviewed the
vent and determined the outcome classification.
Hospital stay for HF was defined for a clinical
yndrome with a minimum 1-night hospital stay
nd involving at least 2 of the following: paroxysmal
octurnal dyspnea, orthopnea, elevated jugular ve-
ous pressure, pulmonary rales, a third heart sound,
ardiomegaly on chest radiography, or pulmonary
e
a
f
m
d
f
o
t
v
O
p
g
H
l
c
h
r
t
m
t
h
f
w
D
c
1
w
W
a
u
o
a
s
C
w
d
a
m
v
0
d
c
o
b
o
V
s
(
v
t
s
f
w
O
w
p
c
F
H
F
H
s
A
p
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 , 2 0 0 9
J A N U A R Y 2 0 0 9 : 1 1 – 2 0
Stevens et al.
TTE Heart Failure Index
14dema on chest radiography. These clinical signs
nd symptoms must have represented a clear change
rom the normal clinical state of the patient and
ust have been accompanied by either failing car-
iac output as determined by peripheral hypoper-
usion (in the absence of other causes such as sepsis
r dehydration) or peripheral or pulmonary edema
reated with intravenous diuretics, inotropes, or
asodilators.
ther participant characteristics. Each patient com-
leted a detailed questionnaire that included age,
ender, race, medical history (including history of
F), level of physical activity, current smoking, and
evel of alcohol consumption. Study personnel re-
orded all current medications and measured
eight, weight, and blood pressure. Medication was
ecorded by having subjects bring medication bot-
les to the baseline interview and categorize the
edications according to Epocrates Rx (San Ma-
eo, California). Total, low-density lipoprotein, and
igh-density lipoprotein cholesterol were measured
rom fasting serum samples. Creatinine clearance
as determined with 24-h urine sample (17).
evelopment of TTE Heart Failure Index. We first
alculated correlation coefficients among all of the
5 candidate variables and eliminated variables that
ere highly correlated (r  0.4) with one another.
hen 2 variables were highly correlated with one
nother, the 1 that was a stronger predictor in
nivariate unadjusted analysis was chosen and the
ther eliminated. We then evaluated the strength of
ssociation between each candidate variable and
ubsequent hospital stay for HF, with age-adjusted
ox proportional hazards models. To determine
hich of these candidate variables were indepen-
ent predictors of HF, we simultaneously entered
ll variables into a single proportional hazards
odel.
From this multivariable model, we selected all
ariables that independently predicted HF (at p 
.05) to be included in the Heart Failure Index. To
evelop the Heart Failure Index, we first chose
ut-points to determine an abnormal value for each
f the 5 variables with reference ranges established
y the American Society of Echocardiography and
ther studies: LVMI90 g/m2; LAVI29 ml/m2;
TILVOT 22 mm; DD as pseudonormal or re-
trictive; and MR as mild, moderate, or severe
4,7,9,10,18). We then entered all of these index
ariables into a single multivariable Cox propor-
ional hazards model and assigned points corre-
ponding to the hazard ratios for abnormal values
or each index variable. Each subject’s index scoreas calculated as the sum of points on this index.
f note, if a measurement was missing, “0” points
as recorded for that single measurement, but the
atient’s other measurements would be tallied to
alculate the index score.
To evaluate the prognostic value of the Heart
ailure Index, we calculated the relative hazard of
F hospital stay according to score on the Heart
ailure Index, adjusted for age, gender, history of
F, hypertension, myocardial infarction, diabetes,
moking, renal insufficiency, and body mass index.
nother analysis was done, adjusting for N-terminal
art of the pro-B-type natriuretic peptide (NT-
Table 1. Baseline Characteristics of 1,024 Participants With
Coronary Heart Disease
Age, yrs 67 11
Male 840 (82)
Race
White 615 (60)
Black 168 (16)
Asian 118 (12)
Other 122 (12)
Medical history
Hypertension 723 (71)
MI 547 (54)
Stroke 148 (15)
Diabetes 265 (26)
Revascularization 602 (59)
Asthma/COPD 163 (16)
CHF 179 (18)
Renal insufﬁciency (CrCl 60) 236 (24)
Measured characteristics
LVEF 0.62 0.10 (0.13–0.83)
SBP 133 21 (90–235)
DBP 75 11
LDL 104 34
HDL 46 14
BMI 28.4 5.3
BSA 1.95 0.22
Use of medications
Beta-blocker 593 (58)
ACE inhibitor 524 (51)
Statin 657 (64)
Aspirin 792 (77)
Behavioral risk factors
Physically inactive 371 (36)
Current smoking 201 (20)
Regular alcohol use 293 (29)
Values given as n (%) or mean  SD with values in parentheses as ranges.
ACE  angiotensin-converting enzyme; BMI  body mass index; BSA 
body surface area; CHF  congestive heart failure; COPD  chronic obstruc-
tive pulmonary disease; CrCl  creatinine clearance; DBP diastolic blood
pressure; HDL  high-density lipoprotein (cholesterol); LDL  low-density
lipoprotein (cholesterol); LVEF  left ventricular ejection fraction; MI 
myocardial infarction; SBP  systolic blood pressure.
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15roBNP); EF; and size and treatment of myocardial
nfarction via wall motion score, revascularization,
nd medication use (beta-blocker, angiotensin-
onverting enzyme inhibitor, statin, and aspirin)
19). To evaluate whether this index predicts inci-
ent HF, we repeated this analysis in patients
ithout a self-reported history of HF. We verified
he proportionality assumptions of all models. All
nalyses were performed with Statistical Analysis
oftware (version 8, SAS Institute Inc., Cary,
orth Carolina).
E S U L T S
f the 1,024 participants, 1,015 (99%) provided
n average 4.4 years of follow-up. Baseline charac-
eristics of the participants are described in Table 1.
f the 15 candidate variables, 2 were initially
liminated because they were highly correlated (r 
.4) with other candidate variables: LV end-
iastolic volume index (highly correlated with end-
ystolic volume index) and VTIRVOT (highly corre-
ated with VTILVOT). All of the remaining 13
Table 2. Association of 13 Baseline TTE Variables With Hospital
Variable*
Age-Adjusted HR
(95% CI)
LVESVI 1.6 (1.5–1.8)
Aortic valve area* 1.4 (1.2–1.6)
MR
None to trace reference
Mild 2.4 (1.7–3.5)
Moderate or severe 10.2 (4.4–23.5)
Tricuspid regurgitation
None to trace reference
Mild 1.5 (1.1–2.3)
Moderate or severe 6.4 (2.6–15.8)
Right atrial pressure 1.3 (1.2–1.4)
Left atrial volume index 1.8 (1.6–2.0)
LVMI 1.8 (1.6–2.0)
Wall motion score index 1.5 (1.3–1.6)
Pulmonary artery systolic pressure 1.5 (1.2–1.8)
LVEF* 1.7 (1.5–2.0)
VTILVOT* 1.9 (1.5–2.3)
Right atrial volume index 1.6 (1.4–1.9)
Diastolic dysfunction
Normal reference
Impaired relaxation 2.2 (1.4–3.5)
Pseudonormal or restrictive 5.5 (3.1–9.7)
*Entered per standard deviation decrease; all other continuous variables entered
CI  conﬁdence interval; HF  heart failure; HR  hazard ratio; LVEF  left ven
left ventricular mass index; MR  mitral regurgitation; TTE  transthoracic echocaandidate variables were significant univariate pre- sictors of HF, 5 were independent predictors of HF:
R, LAVI, LVMI, VTILVOT, and DD (Table 2).
We entered these 5 variables into a single mul-
ivariable model and calculated TTE Heart Failure
ndex points by dividing each variable’s hazard ratio
y 1.6, which was the lowest HR. The resulting
TE Heart Failure Index ranged from 0 to 8
oints, with 1 point for MR (mild, moderate, or
evere), LAVI (29 ml/m2), and VTILVOT (22
m); 2 points for DD (pseudonormal or restric-
ive); and 3 points for LVMI (90 g/m2) (Table 3).
Among participants with 0 to 2 points, 4% had
F hospital stays (reference); among those with 3
o 4 points: 10% had HF hospital stays (hazard ratio
HR]: 2.4; 95% confidence interval [CI]: 1.3 to 4.4,
 0.003); among those with 5 to 6 points, 24%
ad HF hospital stays (HR: 6.2; 95% CI: 3.6 to
0.6, p  0.0001); and among those with 7 to 8
oints, 48% had HF hospital stays (HR: 13.7; 95%
I: 7.2 to 25.9, p  0.0001) (Fig. 1). Associations
ere somewhat attenuated but remained strong
fter further adjustment for gender, history of HF,
moking, renal insufficiency, history of hyperten-
ys for HF During 4.4 Years of Follow-Up
p Value
Adjusted HR
(95% CI)† p Value
0.0001 1.2 (0.8–1.7) 0.44
0.0003 1.2 (0.9–1.5) 0.15
0.0001 1.7 (1.0–2.9) 0.05
0.0001 2.2 (0.4–13.1) 0.38
0.02 0.9 (0.5–1.6) 0.70
0.0001 0.3 (0.04–2.5) 0.28
0.0001 1.2 (1.0–1.5) 0.11
0.0001 1.4 (1.1–1.8) 0.01
0.0001 1.5 (1.2–1.8) 0.0001
0.0001 0.9 (0.7–1.2) 0.57
0.0001 0.9 (0.7–1.5) 0.57
0.0001 1.0 (0.7–1.4) 0.99
0.0001 1.3 (1.0–1.8) 0.05
0.0001 1.1 (0.9–1.4) 0.46
reference
0.0003 1.4 (0.8–2.3) 0.22
0.0001 2.3 (1.1–5.0) 0.04
tandard deviation increase. †Adjusted for age plus all other candidate variables.
lar ejection fraction; LVESVI  left ventricle end-systolic volume index; LVMI 
raphic; VTILVOT  left ventricular outﬂow tract velocity–time integral.Sta
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16iabetes, and body mass index. We performed a
eparate subgroup analysis to adjust for EF, size and
reatment of myocardial infarction (wall motion
core, revascularization, and medication use with
eta blockers, angiotensin-converting enzyme in-
ibitors, statins, and aspirin), and NT-proBNP
Table 4).
Of the 831 participants without a baseline history
f HF, among those with 0 to 2 points, 3% had HF
ospital stays (reference); among those with 3 to 4
oints, 7% had HF hospital stays (HR: 2.6; 95%
I: 1.2 to 5.9, p  0.02); among those with 5 to 6
oints, 23% had HF hospital stays (HR: 9.4; 95%
I: 4.6 to 19.4, p 0.0001); among those with 7 to
points, 39% had HF hospital stays (HR: 16.4;
5% CI: 6.9 to 38.8, p  0.0001) (Fig. 2, Table 5).
The TTE Heart Failure Index plus age, LVEF,
nd NT-proBNP was compared in a receiver-
perating characteristic curve (c  0.86) with age,
HF Index Score
23/219*
HR 2.8
3
31/176*
HR 4.3
4
31/110*
HR 5.7
5
22/47*
HR 10.2
6
13/21*
HR 31.7
7, 8
ailure Index: Risk Stratiﬁcation of HF Hospital Stay by Score
Patients
iographic (TTE) Heart Failure Index predicts heart failure (HF) hos-
ith stable coronary artery disease (CAD). The Heart Failure Index
ints, representing risk as follows: 3 points for left ventricular mass
tolic dysfunction, and 1 point for left ventricular outﬂow tract
mitral regurgitation, and left atrial volume index. The graph shows
hospital stay per increasing score on the index. This can be used
ts with stable CAD. p  0.05, adjusted for age, gender, body
action, renal insufﬁciency, history of heart failure, myocardial
n, and diabetes. *Number of participants hospitalized for HF/num-
Table 3. Heart Failure Index Score Deﬁnitions: 5 Variable Mode
TTE HF Index Measurements
Abnormalities
With Measu
Mild, moderate, or severe MR 196/1,0
LAVI 29 ml/m2 580/1,0
LVMI 90 g/m2 565/1,0
VTILVOT 22 mm 547/985
Pseudonormal or restrictive diastolic function 116/903
*Adjusted for the other 5 TTE variables as well as age.
LAVI  left atrial volume index; other abbreviations as in Table 2.l
art Failure Index score. HR  hazard ratio.VEF, and NT-proBNP alone (c  0.84, p 
.09) (Fig. 3).
I S C U S S I O N
here is an abundance of transthoracic echocardio-
raphic measurements with predictive value. Thus
ar, there has not been a prior effort to sort through
hem and identify those with independent and
ncremental value in predicting HF. In an ambula-
ory cohort of patients with stable CAD, we eval-
ated 15 candidate TTE measurements to see
hich were independent predictors of HF hospital
tay. The 5 measurements that were independent
redictors were combined into an index that incre-
entally stratifies patients according to their risk of
F. Furthermore, we did a subgroup analysis
mong the 831 patients without a history of HF
nd showed that the index predicts incident HF.
In creating this index, we initially studied a group
f 15 historically and intuitively promising echocar-
iographic measurements. By choosing the most
redictive among them, we eliminated those that
ere statistically redundant, leaving those that were
ndependent predictors of HF: LVMI, LAVI, MR,
TILVOT, and DD (Table 3). Accordingly, the
eart Failure Index, derived from these 5 measure-
ents, presents compelling evidence that these
easurements be routinely performed in most clin-
cal settings. Additionally, combining the aggregate
nformation of these measurements allows the cli-
ician or researcher to simplify the wealth of infor-
ation into a single number. Routine calculation of
his value might streamline communication among
ealth care providers and scientists.
Each of the 5 parameters included in the index
ave data to support their prognostic value (2–7).
et, standing alone as individual measurements,
ach examines a relatively narrow window of patho-
hysiology. Hence, as might be anticipated, each is
imary Outcome Is HF
mber
ent
Adjusted HR
(95% CI)* p Value
Points Assigned
to Index
1.8 (1.2–2.8) 0.009 1
1.6 (1.0–2.5) 0.06 1
4.1 (2.3–7.2) 0.0001 3
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Table 4. Association of Heart Failure Index Score With Hospital Stay for HF During 4.4 Years of Follow-Up Among 1,015 Participants With Coronary Artery Disease
Index
Score
% With
Events
Age-Adjusted HR
(95% CI) p Value
MV-Adjusted HR
(95% CI)* p Value
MI Size/Treatment-
Adjusted HR
(95% CI)† p Value
EF-Adjusted HR
(95% CI)‡ p Value
NT-proBNP–adjusted HR
(95% CI)§ p Value
0–2 4% (17/397) reference — reference — reference — reference — reference —
3–4 10% (32/313) 2.4 (1.3–4.4) 0.003 1.9 (0.9–3.9) 0.08 2.0 (1.0–4.2) 0.06 2.0 (0.9–4.1) 0.07 1.9 (0.9–4.1) 0.09
5–6 24% (63/259) 6.2 (3.6–10.6) 0.0001 4.1 (2.1–8.1) 0.0001 4.5 (2.2–9.2) 0.0001 3.9 (1.9–8.1) 0.0003 3.0 (1.4–6.5) 0.006
7–8 48% (22/46) 13.7 (7.2–25.9) 0.0001 9.1 (4.1–20.1) 0.0001 10.1 (4.4–23.4) 0.0001 9.6 (4.2–22.0) 0.0001 4.3 (1.7–11.0) 0.002
*Adjusted for age, gender, history of HF, smoking, renal insufﬁciency, history of hypertension, history of myocardial infarction, history of diabetes, and body mass index. †Adjusted for above variables plus: 1) resting wall motion score; 2) prior
revascularization; and 3) medication use (beta-blocker, ACE, aspirin, statin). ‡Adjusted for above variables plus EF. §Adjusted for above variables plus log N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP).
Abbreviations as in Tables 1 and 2.
Table 5. Association of Heart Failure Index Score With Hospital Stay for HF During 4.4 Years of Follow-Up Among 831 Participants Without a History of HF
Index
Score
% With
Events
Age-Adjusted HR
(95% CI) p Value
MV-Adjusted HR
(95% CI)* p Value
MI Size/Treatment-
Adjusted HR
(95% CI)† p Value
EF-Adjusted HR
(95% CI)‡ p Value
NT-proBNP–Adjusted HR
(95% CI)§ p Value
0–2 3% (9/360) reference — reference — reference — reference — reference —
3–4 7% (17/259) 2.6 (1.2–5.9) 0.02 2.0 (0.8–5.3) 0.15 1.8 (0.7–4.9) 0.22 1.7 (0.6–4.5) 0.29 2.0 (0.7–5.6) 0.18
5–6 23% (42/185) 9.4 (4.6–19.4) 0.0001 6.9 (2.9–16.6) 0.0001 6.8 (2.7–16.6) 0.0001 5.3 (2.1–13.4) 0.0004 4.2 (1.5–11.5) 0.006
7–8 39% (13/33) 16.4 (6.9–38.8) 0.0001 11.0 (3.9–30.9) 0.0001 9.5 (3.3–27.4) 0.0001 8.4 (2.9–23.9) 0.0001 5.7 (1.8–17.8) 0.003
*Adjusted for age, gender, smoking, renal insufﬁciency, history of hypertension, history of myocardial infarction, history of diabetes, and body mass index. †Adjusted for above variables plus: 1) resting wall motion score; 2) prior revascularization;
and 3) medication use (beta-blocker, ACE, aspirin, statin). ‡Adjusted for above variables plus EF. §Adjusted for above variables plus log N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP).
Abbreviations as in Tables 1 and 2.
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18hen used in combination, however, the index
ecruits the potency of echocardiography for defin-
ng clinical risk and potentially influencing clinical
anagement (Fig. 1).
It is noteworthy that EF was not included in the
ndex. Two reasons justify excluding EF from the
ndex: first, there was not a large proportion of
atients in this study with reduced EF (92.7% with
ailure Index: Risk Stratiﬁcation of HF Hospital Stay by Score
nts Without History of HF at Baseline
Index predicts HF hospital stays in subgroup analysis of 831
D and no history of HF. The Heart Failure Index ranged from 0 to
risk as follows: 3 points for LVMI; 2 points for diastolic dysfunc-
ft ventricular outﬂow tract velocity-time integral, mitral regurgita-
ume index. The graph shows risk stratiﬁcation for HF hospital stay
the index. This can be used to predict incident HF in patients
o history of HF. p  0.05. *Number of participants hospitalized
ven TTE Heart Failure Index score. Abbreviations as in Figure 1.
gestive HF Hospital Stay Comparing the TTE Heart Failure
BNP, and Age With EF and NT-proBNP Alone
Index can be an adjunct to age, left ventricular ejection fraction
part of the pro-B-type natriuretic peptide (NT-proBNP) to predict
perating characteristic (ROC) curve shown in the ﬁgure (c  0.86).
th the ROC curve of age, LVEF, and NT-proBNP (Model A, c e
viations as in Figure 1.F 45%, mean 62  10%), making it a relative
eak predictor in our cohort; and second, we
ddressed its potential effect on the index by adjust-
ng for it in the multivariate analysis. We also would
ike to draw attention to the TTE Heart Failure
ndex’s unique role in identifying diastolic HF,
iven the relatively preserved EF in this patient
opulation and that DD, LV mass, and left atrial
olume make up 6 of the index’s 8 points.
Some candidate variables were not included in
he index because they were not independent pre-
ictors of HF but notably have a rich history
upporting their role in predicting poor cardiovas-
ular outcomes, mortality, and HF. For example,
olumetric assessment of the LV (end-systolic vol-
me index and end-diastolic volume index) is
nown to be strongly predictive of HF and mortal-
ty (20,21). Meanwhile, pulmonary artery systolic
ressure is a surrogate for right HF, often the end
tage of a decompensating heart (22). In advanced
F these measurements certainly are imperative to
ssessment but might become abnormal in later
tages of HF than that seen in the Heart and Soul
atient population. Therefore, the TTE Heart Fail-
re Index might be most suitable for predicting HF
n a patient population with relatively preserved
ystolic function. Also, many of the measurements
ere much stronger univariate predictors than in-
ependent predictors, suggesting they might have
een eliminated merely because they were corre-
ated to the other echocardiographic measurements
Table 2).
tudy limitations. Several limitations must be con-
idered when interpreting the results of our study.
irst, the Veterans Affairs hospital has a unique and
omogenous patient population proportionally
ominated by Caucasian (60%) men (82%) with a
ean age of 67  11 years. Therefore, to validate
he TTE Heart Failure Index and to prove gener-
lizability, the index must be applied to another
opulation of patients with stable CAD. Second,
he primary outcome is HF hospital stay, which
ight be prone to error despite rigorous adjudica-
ion, depending on clinical assessment, coding, and
ccuracy of chart review. Third, the TTE Heart
ailure Index was limited to TTE measurements
vailable at the time of the initial echocardiographic
xamination. Therefore we were unable to incorpo-
ate newer techniques in echocardiography, such as
issue Doppler imaging, which have proven prog-
ostic value (23). Fourth, we also included variables
hat might not be measured routinely in commonFigure 2. TTE Heart F
Increase in 831 Patie
The TTE Heart Failure
patients with stable CA
8 points, representing
tion; and 1 point for le
tion, and left atrial vol
per increasing score on
with stable CAD and nFigure 3. ROC for Con
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19o maximize the prognostic value of the index and
erhaps to stimulate expanded use in clinical
ractice, we included VTILVOT in the final index,
ecause it was 1 of the 5 independent predictors
f HF hospital stay in the 13-variable model.
ifth, creating an index from multiple echocar-
iographic variables is limited by the correlation
f the various measurements to each other. We
ccounted for this by eliminating those variables
ighly correlated to each other (r  0.4). For
xample, VTIRVOT was excluded because of its
elationship to VTILVOT.
Finally, the index uses dichotomous cut-offs for
ach measurement. However, the severity of each
bnormality beyond that cut-off is not taken into
ccount, thereby potentially losing incrementalmitral regurgitation: long-term out-
come and prognostic implications timation of right vO N C L U S I O N S
he TTE Heart Failure Index is a unique combi-
ation of 5 measurements that independently pre-
ict HF when compared in a multivariate analysis.
hese 5 measurements are: LVMI, LAVI, MR,
TILVOT, and DD (Table 3). The index effectively
tratifies patients with stable CAD according to
heir risk of HF hospital stay in a manner more
seful than any 1 of the aforementioned measure-
ents alone. Further studies are needed to elucidate
he value of this index in clinical decision-making in
atients with CAD as well as other forms of
ardiomyopathy.
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